These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1960 related items for PubMed ID: 31838007

  • 1. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD, trial investigators.
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [Abstract] [Full Text] [Related]

  • 2. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
    Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC, trial investigators.
    Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
    [Abstract] [Full Text] [Related]

  • 3. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS.
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [Abstract] [Full Text] [Related]

  • 4. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
    Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG.
    Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
    [Abstract] [Full Text] [Related]

  • 5. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
    Cho BC, Chiu CH, Massarelli E, Buchschacher GL, Goto K, Overbeck TR, Loong HHF, Chee CE, Garrido P, Dong X, Fan Y, Lu S, Schwemmers S, Bordogna W, Zeuner H, Osborne S, John T.
    Lung Cancer; 2024 Feb; 188():107442. PubMed ID: 38171156
    [Abstract] [Full Text] [Related]

  • 6. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
    Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A, Fox E.
    Neuro Oncol; 2022 Oct 03; 24(10):1776-1789. PubMed ID: 35395680
    [Abstract] [Full Text] [Related]

  • 7. Evolving role of entrectinib in treatment of NTRK-positive tumors.
    Chawla N, Bui NQ, Seetharam M.
    Future Oncol; 2021 Aug 03; 17(22):2835-2846. PubMed ID: 33896226
    [Abstract] [Full Text] [Related]

  • 8. The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements.
    Delgado J, Pean E, Melchiorri D, Migali C, Josephson F, Enzmann H, Pignatti F.
    ESMO Open; 2021 Apr 03; 6(2):100087. PubMed ID: 33735800
    [Abstract] [Full Text] [Related]

  • 9. NTRK fusion-positive cancers and TRK inhibitor therapy.
    Cocco E, Scaltriti M, Drilon A.
    Nat Rev Clin Oncol; 2018 Dec 03; 15(12):731-747. PubMed ID: 30333516
    [Abstract] [Full Text] [Related]

  • 10. Targeting TRK family proteins in cancer.
    Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS.
    Pharmacol Ther; 2017 May 03; 173():58-66. PubMed ID: 28174090
    [Abstract] [Full Text] [Related]

  • 11. NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors.
    Kim EE, Park CK, Kim SK, Phi JH, Paek SH, Choi JY, Kang HJ, Lee JH, Won JK, Yun H, Park SH.
    Acta Neuropathol Commun; 2024 Jul 16; 12(1):118. PubMed ID: 39014476
    [Abstract] [Full Text] [Related]

  • 12. Clinical characteristics and treatment patterns of patients with NTRK fusion-positive solid tumors: A multisite cohort study at US academic cancer centers.
    Willis C, Au T, Hejazi A, Griswold C, Schabath MB, Thompson J, Malhotra J, Federman N, Ko G, Appukkuttan S, Warnock N, Kong SX, Hocum B, Brixner D, Stenehjem D.
    J Manag Care Spec Pharm; 2024 Jul 16; 30(7):672-683. PubMed ID: 38950155
    [Abstract] [Full Text] [Related]

  • 13. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
    Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Farago AF, Lin CC, Karapetis CS, Li YC, Day BM, Chen D, Wilson TR, Barlesi F.
    J Clin Oncol; 2021 Apr 10; 39(11):1253-1263. PubMed ID: 33646820
    [Abstract] [Full Text] [Related]

  • 14. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
    Frampton JE.
    Drugs; 2021 Apr 10; 81(6):697-708. PubMed ID: 33871816
    [Abstract] [Full Text] [Related]

  • 15. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
    Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D, Costa DB, Multani PS, Li GG, Hornby Z, Chow-Maneval E, Luo D, Lim JE, Iafrate AJ, Shaw AT.
    J Thorac Oncol; 2015 Dec 10; 10(12):1670-4. PubMed ID: 26565381
    [Abstract] [Full Text] [Related]

  • 16. FDA Approval Summary: Entrectinib for the Treatment of NTRK gene Fusion Solid Tumors.
    Marcus L, Donoghue M, Aungst S, Myers CE, Helms WS, Shen G, Zhao H, Stephens O, Keegan P, Pazdur R.
    Clin Cancer Res; 2021 Feb 15; 27(4):928-932. PubMed ID: 32967940
    [Abstract] [Full Text] [Related]

  • 17. [Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion].
    Delaye M, Rodrigues M.
    Bull Cancer; 2020 Nov 15; 107(11):1085-1086. PubMed ID: 33169692
    [No Abstract] [Full Text] [Related]

  • 18. Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.
    Paz-Ares L, Barlesi F, Siena S, Ahn MJ, Drilon A, Conley A, Rolfo C, Wolf J, Seto T, Doebele R, Kapre A, Chen D, McCallum S, Osborne S, Demetri G.
    ESMO Open; 2021 Jun 15; 6(3):100113. PubMed ID: 33930659
    [Abstract] [Full Text] [Related]

  • 19. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.
    Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Lin JJ, Goto K, Lee J, Bazhenova L, John T, Fakih M, Chawla SP, Dziadziuszko R, Seto T, Heinzmann S, Pitcher B, Chen D, Wilson TR, Rolfo C.
    Clin Cancer Res; 2022 Apr 01; 28(7):1302-1312. PubMed ID: 35144967
    [Abstract] [Full Text] [Related]

  • 20. Tropomyosin receptor kinase inhibitors in the management of sarcomas.
    Wilding CP, Loong HH, Huang PH, Jones RL.
    Curr Opin Oncol; 2020 Jul 01; 32(4):307-313. PubMed ID: 32541318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 98.